A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Clinical trial NCT04557059 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04557059
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-12
- Primary completion
- 2029-08-27
- Enrollment
- 692
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.